Updated Efficacy and Safety of Melflufen in Patients with Relapsed/Refractory Multiple Myeloma Refractory to Daratumumab and/or Pomalidomide: HORIZON (OP-106)

Por: Richardson, PG, Oriol, A, Larocca, A, Rodriguez-Otero, P, Norkin, M, Blade, J, Cavo, M, Hassoun, H, Leleu, X, Alegre, A, Maisel, C, Paner, A, Mazumder, A, Zonder, JA, Puig, N, Harran, J, Harmenberg, J, Thuresson, S, Zubair, H and Mateos, MV

---

Publicada: 1 nov 2019

---

---

Filiaciones:
Richardson, PG:
 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

:
 Hosp Badalona Germans Trias & Pujol, Barcelona, Spain

Larocca, A:
 AOU Citta Salute & Sci TorinoSC Ematol U, Turin, Italy

Rodriguez-Otero, P:
 Clin Univ Navarra, Madrid, Spain

Norkin, M:
 Univ Florida, Hlth Canc Ctr, Gainesville, FL 32611 USA

Blade, J:
 Hosp Clin Barcelona, Serv Oncohematol, Barcelona, Spain

Cavo, M:
 St Orsola Marcello Malpighi Hosp, Bologna, Italy

Hassoun, H:
 Mem Sloan Kettering Canc Ctr, Manhattan, KS USA

Leleu, X:
 CHU Poitiers, Poitiers, France

Alegre, A:
 Hosp Univ La Princesa, Madrid, Spain

Maisel, C:
 Baylor Scoot & White Charles A Sammons Canc Ctr, Dallas, TX USA

Paner, A:
 Rush Univ, Med Ctr, Chicago, IL 60612 USA

Mazumder, A:
 Oncol Inst Hope & Innovat, Anaheim, CA USA

Zonder, JA:
 Karmanos Canc Inst, Detroit, MI USA

Puig, N:
 Hosp Clin Univ Salamanca, Salamanca, Spain

Harran, J:
 Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA

Harmenberg, J:
 Oncopeptides AB, Stockholm, Sweden

Thuresson, S:
 Oncopeptides AB, Stockholm, Sweden

Zubair, H:
 Oncopeptides AB, Stockholm, Sweden

Mateos, MV:
 Hosp Clin Univ Salamanca, Salamanca, Spain